Arvinas, Inc (ARVN) — 分析摘要
Arvinas, Inc（ARVN）的市值为549.24百万美元，最近一年的营收同比增长了-0.3%。净利润率为-30.8%。当前市盈率为59.1倍。
核心要点
- 营收同比变化-0.3%
- 净利润率-30.8%
- 市盈率59.1倍
与PHARMACEUTICAL PREPARATIONS板块的其他公司相比，ARVN的营收增长为-0.3%，市盈率为59.1倍。
Arvinas, Inc (ARVN)
更新 — ET · 市场数据 POLYGON · 财务数据 SEC EDGAR
红旗与风险提示重点关注
当前存在需要关注的风险信号，应与估值结果一并解读。
最新报表显示自由现金流为负。
经营现金流为负，但净利润仍为正。
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.
行业
PHARMACEUTICAL PREPARATIONS
员工人数
246
总部
NEW HAVEN, CT
Exchange
XNAS
基于 4 年财务数据的系统性竞争优势评估
此评估基于历史财务数据的量化分析，不构成投资建议。护城河评级可能随行业和竞争环境变化。
首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。
资本结构
现金流
免责声明：本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。